Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

NYU Langone Medical Center announced today the U.S. Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs has awarded Silvia Formenti, MD, the Sandra and Edward Meyer Professor and Chair of the Department of Radiation Oncology a $4.5 million Multi-Team Award to conduct novel breast cancer research.

21 Apr 2011

RaySearch receives order for its RayStation system from RISO

RaySearch Laboratories AB has received an order for its RayStation treatment planning system from RISO, the Radiotherapeutic Institute in Deventer, the Netherlands.

19 Apr 2011

Varian Medical Systems launches new brachytherapy applicator

Varian Medical Systems is introducing a new brachytherapy applicator for treating endometrial cancer patients after a hysterectomy. The Capri applicator, aimed at increasing patient comfort and allowing clinicians to better sculpt the radiotherapy dose, is being exhibited this week at the annual American Brachytherapy Society meeting in San Diego.

15 Apr 2011

Targeted photodynamic therapy eradicates some models of cancer

Targeted photodynamic therapy can completely eradicate some models of cancer, according to the latest research by UK and Swiss scientists, published in the current issue of the British Journal of Cancer.

12 Apr 2011

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Soy isoflavones can improve radiotherapy for lung cancer cells

A component in soybeans increases radiation's ability to kill lung cancer cells, according to a study published in the April issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.

1 Apr 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Prostate cancer updates

A Hunter-based prostate cancer support group says ground-breaking research by the University of Newcastle will help save many lives in the region. This new work has found patients with localized advanced prostate cancer can double their chances of survival by undertaking hormone therapy in combination with radiology treatment. This comes from a 10 year trial, coordinated by the University's Professor Jim Debnam.

28 Mar 2011

Concord Medical fourth quarter total net revenues increase 30.1% to RMB112.9 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2010.

28 Mar 2011

Everist Genomics announces global launch of OncoDefender-CRC colorectal cancer assay

Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.

28 Mar 2011

Simulated acupuncture can treat nausea effectively in cancer patients undergoing radiotherapy

Simulated acupuncture - sometimes referred to as placebo - is just as beneficial as real acupuncture for treating nausea in cancer patients undergoing radiotherapy, according to a study from Karolinska Institutet and Linköping University in Sweden. Patients, who received only standard care including medications for nausea, felt significant more nausea than patients in both the acupuncture groups.

24 Mar 2011

Statins improve outcomes in high-risk prostate cancer patients treated with definitive radiation therapy

Men with high-risk prostate cancer who take statin drugs commonly used to lower cholesterol while receiving radiation therapy are less likely to have their cancer return than patients who do not take these medications, according to a study published in the March issue of the International Journal of Radiation Oncology-Biology-Physics, an official journal of the American Society for Radiation Oncology (ASTRO).

24 Mar 2011

John Muir Health provides new cancer treatment using Varian's RapidArc radiation therapy

John Muir Health is offering a new cancer treatment option using the latest technology from Varian Medical Systems - The Trilogy Linear Accelerator with RapidArc Technology. The new accelerator, located at John Muir Medical Center, Concord, significantly shortens treatment sessions from 15-20 minutes to 2-5 minutes, while improving the precision of the radiotherapy.

24 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011